# A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Study · id `cardio:ct-nct07219602` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07219602](<https://clinicaltrials.gov/study/NCT07219602>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07219602

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07219602. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-11 (actual); primary completion 2028-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07219602, source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)
- Started: 2025-12-11 (actual) (ClinicalTrials.gov record NCT07219602, source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT07219602, source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT07219602, source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)
- Countries: United States; Czechia; Netherlands; Slovakia (ClinicalTrials.gov record NCT07219602, source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07219602-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
- Acronym: RUBENS
- Condition: Lipidemia
- Condition: Type 2 Diabetes (T2DM)
- Condition: Metabolic Syndrome (MetS)
- Intervention (Drug): obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Intervention (Drug): Obicetrapib 10 mg
- Intervention (Other): Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)

## Provenance

Content hash: 606aab18eba182a13db6babcc73adffd9b461d6128248f9f91146608603f5e70
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
